In the rare studies where PD-L1 blocking antibody was tested against colorectal cancer metastasis growing in the liver, the blocking antibody was administered intraperitoneally whereas in clinical trials, anti-PD-1/PD-L1 checkpoint inhibitors are administered intravenously23,33,34. This evidence concerns the gene CD274 and colorectal cancer.